Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, April 25th. Analysts expect Alexion Pharmaceuticals to post earnings of $1.50 per share for the quarter. Alexion Pharmaceuticals has set its FY18 guidance at $6.60-6.80 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the prior year, the business earned $1.26 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, analysts expect Alexion Pharmaceuticals to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Alexion Pharmaceuticals stock opened at $113.28 on Wednesday. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The firm has a market capitalization of $24,766.27, a PE ratio of 21.95, a price-to-earnings-growth ratio of 1.00 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34.
In related news, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $707,048.49. Following the completion of the sale, the chief financial officer now directly owns 95,093 shares of the company’s stock, valued at approximately $11,060,266.83. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Heidi L. Wagner sold 655 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the sale, the senior vice president now directly owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,700 shares of company stock valued at $3,345,708. Company insiders own 4.35% of the company’s stock.
ALXN has been the subject of several recent research reports. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. UBS lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Thursday, January 4th. Alex. Brown reissued an “outperform” rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Credit Suisse Group reissued an “outperform” rating and issued a $147.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, January 18th. Finally, Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and twenty have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $155.95.
TRADEMARK VIOLATION WARNING: This piece was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/18/alexion-pharmaceuticals-alxn-scheduled-to-post-earnings-on-wednesday.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.